Group 1 - The company and its subsidiaries have a total of 218 products included in the new National Medical Insurance Drug List, with 94 classified as Category A and 124 as Category B [1] - Notable products include injectable Aripiprazole microspheres, which were included through negotiation, and injectable Triptorelin microspheres, which have a new indication [1] - The inclusion of these products is expected to enhance market expansion and improve drug accessibility, positively impacting the company's future operating performance [1] Group 2 - The new Medical Insurance Drug List will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - Injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - Injectable Triptorelin acetate microspheres have a new indication added, and Injectable Esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The core announcement is that 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - Notable inclusions are the injectable Aripiprazole microspheres, which are newly negotiated for inclusion, and the injectable Triptorelin acetate microspheres, which have a new indication added [1] - The company expects that the inclusion of these products will help expand market access and improve drug availability, positively impacting future operating performance [1] Group 2 - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1] - There are no products from the company that have exited the National Medical Insurance Directory [1]

Core Viewpoint - The announcement by the company regarding the inclusion of 194 products in the National Medical Insurance Directory for 2025, which is a significant development for its product portfolio [1] Group 1: Product Inclusion - A total of 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication, while the injectable Esomeprazole sodium has successfully renewed its contract [1]

Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]

Core Viewpoint - Health元药业集团股份有限公司 has successfully had 218 products included in the new National Medical Insurance Directory, which is expected to positively impact the company's future operating performance, although it will not have a significant effect in the current period [1]. Group 1: Stock Performance - As of December 8, 2025, Health元's stock closed at 12.54 yuan, down 0.79% from the previous trading day, with a total market capitalization of 22.941 billion yuan [1]. - The stock opened at 12.63 yuan, reached a high of 12.76 yuan, and a low of 12.48 yuan, with a trading volume of 2.51 billion yuan and a turnover rate of 1.09% [1]. Group 2: Product Inclusion in National Medical Insurance Directory - On December 7, 2025, the National Medical Insurance Bureau released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, which includes 218 products from Health元 and its subsidiaries [1]. - Among the included products, 94 are classified as Category A and 124 as Category B [1]. - Notable inclusions are the injectable Aripiprazole microspheres and the injectable Triptorelin acetate microspheres, which now have an added indication for endometriosis [1]. - The renewal of the Tobramycin inhalation solution and injectable Esomeprazole sodium was also successful, with no products being removed from the directory [1]. - The new directory will take effect on January 1, 2026, and while it is expected to have a positive impact on future sales, the sales performance remains subject to policy and market uncertainties [1].

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本集團未有產品退出《國家醫保目錄》。本集团前述產品納入《國家醫保目錄》有助於後 續擴大市場及提高藥品可及性，預計未來將對本公司的經營業績產生積極影響。此版《國 家醫保目錄》將於2026年1月1日正式執行，預計不會對本公司当期經營業績產生重大影響。 2 醫保支付標準、醫保報銷細則等相關資訊需以國家醫保局等相關部門公示的資訊為准。公 司產品未來銷售情況受醫藥行業政策變動、市場環境變化等影響，具有一定的不確定性。 敬請廣大投資者審慎決策，注意投資風險。 公司產品納入國家醫保目錄 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司，統稱「本集團」）自願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 2025年12月7日，國家醫保局、人力資源社會保障部發佈了《國家基本醫療保險、生育保 險和工傷保險藥品目錄（2025年）》（醫保 ...

Core Points - The company, Lizhu Group, announced that it has a total of 194 products included in the National Medical Insurance Directory for 2025, comprising 92 Class A and 102 Class B products [1] - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations, while the injectable Triptorelin acetate microspheres have a new indication added, and the injectable Esomeprazole sodium has successfully renewed its contract [1]

Core Viewpoint - The company Health元 (600380.SH) announced that a total of 218 products from the company and its subsidiaries have been included in the medical insurance catalog, which includes 94 Class A and 124 Class B products [1] Group 1 - The injectable Aripiprazole microspheres have been included in the medical insurance catalog through negotiations [1] - The injectable Acetate Triptorelin microspheres have a newly added indication [1] - The Tobramycin inhalation solution and injectable Esomeprazole sodium have successfully renewed their contracts [1]

Core Viewpoint - The company, Lijun Group, announced that it has successfully included 194 products in the National Medical Insurance Directory for 2025, which includes 92 Class A and 102 Class B products [1] Group 1: Product Inclusion - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication [1] - The injectable Esomeprazole sodium has successfully renewed its contract [1]